Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches.
Ignelzi has played a key role in seven IPOs, and currently serves as the chief financial officer of Karuna Therapeutics.
He joined Karuna in March 2019, coming from scPharmaceuticals, where he was also in the role of chief financial officer, overseeing its transformation to a company preparing for commercial launch.
Prior to scPharmaceuticals, Ignelzi was a senior executive at Juventas Therapeutics, Esperion Therapeutics and Insys Therapeutics, helping raise public and private capital, expand development pipelines through licensing and acquisition and advancing critical therapies, several of which are currently approved by the US Food and Drug Administration.
Ignelzi holds a B.A. in accounting from Ferris State University.
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome.
The company's clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy.
These investigational therapies are grounded in pioneering research published in leading journals including Science, Nature, and Cell to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML